Novel DOAC Reversal Strategies: Update on Best Practices

Novel DOAC Reversal Strategies: Update on Best Practices

Live Webinar
Date Time
Friday, April 26, 2019 12:00pm to 1:00pm ET Register
Monday, April 29, 2019 12:00pm to 1:00pm ET Register
FACULTY

Mark A. Munger, PharmD, FCCP, FACC, FHFSA (Content Presenter/Q&A Faculty)
Professor, Pharmacotherapy
Adjunct Professor, Internal Medicine
Associate Dean, College Affairs, College of Pharmacy
University of Utah Health Sciences Center
Salt Lake City, Utah

Randolph V. Fugit, PharmD, BCPS (Q&A Moderator)
Internal Medicine/Infectious Diseases Clinical Specialist
Director, Antimicrobial Stewardship Program 
VA Rocky Mountain Regional Health Care System
Clinical Associate Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, Colorado

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP (Q&A Faculty)
Professor of Pharmacy Practice and Science
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

PROVIDER STATEMENT

 Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed for Hospital and health-system pharmacists, clinical pharmacists, specialty pharmacists, and other frontline healthcare professionals who are involved in the management of patients treated with DOACs. 

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify current gaps in the management of DOAC-related major bleeding events
  • Describe the mechanisms of action and safety and efficacy data for currently-approved DOAC reversal agents
  • Formulate comprehensive care strategies that facilitate multidisciplinary management of patients at risk for DOAC-related bleeding and address gaps in clinician DOAC knowledge and practice
  • Discuss formulary and policy considerations surrounding DOACs and reversal agents
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by April 18, 2020. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: April 18, 2019
Expiration Date: April 18, 2020
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.

COMMERCIAL SUPPORT

NACCME would like to thank the following companies who have supported the Novel DOAC Reversal Strategies: Update on Best Practices through educational grants and/or in-kind support: Portola Pharmaceuticals, Inc.

CONTINUING EDUCATION

  In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHARMACY

This live, knowledge-based activity (Universal Activity Number JA0006201-0000-19-024-L01-P) has been approved for a maximum of 1.00 contact hours (.100 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 DAYS AFTER ACTIVITY. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers

Kyle R. Copeland, PharmD
Clinical Specialist Pharmacist
Parkwest Medical Center
Assistant Professor
University of Tennessee College of Pharmacy
Knoxville, Tennessee

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Donna Brophy, Angelica DeMaria, Emily Gibson, Jennifer Ilcyn, Randy Robbin, Margaret Stefan and Amanda Steinmayr.

Faculty
The faculty has reported the following:

Dr. Dobesh reports that he is a consultant for: Boehringer Ingelheim, Pfizer/BMS Alliance, Janssen Pharmaceuticals, Daiichi Sankyo, Inc, Portola Pharmaceuticals

Dr. Copeland, Dr. Fugit and Dr. Munger have disclosed no relevant financial relationships with any commercial interest.

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.